Dataset Information

Intratumoral Plasmid IL12 Expands CD8⁺ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy.

ABSTRACT:

Purpose

Triple-negative breast cancer (TNBC) is an aggressive disease with limited therapeutic options. Antibodies targeting programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) have entered the therapeutic landscape in TNBC, but only a minority of patients benefit. A way to reliably enhance immunogenicity, T-cell infiltration, and predict responsiveness is critically needed.

Patients and methods

Using mouse models of TNBC, we evaluate immune activation and tumor targeting of intratumoral IL12 plasmid followed by electroporation (tavokinogene telseplasmid; Tavo). We further present a single-arm, prospective clinical trial of Tavo monotherapy in patients with treatment refractory, advanced TNBC (OMS-I140). Finally, we expand these findings using publicly available bre

SUBMITTER: Telli ML

PROVIDER: S-EPMC8102331 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

Intratumoral Plasmid IL12 Expands CD8⁺ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy.

Purpose

Patients and methods

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy.

Purpose

Patients and methods

OmicsDI is part of the ELIXIR infrastructure

Tweets

Intratumoral Plasmid IL12 Expands CD8⁺ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy.